<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/41907DE0-D69A-49CB-BBCF-A87DE7A3358A"><gtr:id>41907DE0-D69A-49CB-BBCF-A87DE7A3358A</gtr:id><gtr:name>Avan Biotech</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8457F177-72B8-495C-B502-18A1EC2E4EFD"><gtr:id>8457F177-72B8-495C-B502-18A1EC2E4EFD</gtr:id><gtr:name>Flinders University</gtr:name><gtr:address><gtr:line1>Flinders University</gtr:line1><gtr:line2>Sturt Road, Bedford Park</gtr:line2><gtr:line3>GPO Box 2100</gtr:line3><gtr:line4>Adelaide</gtr:line4><gtr:postCode>5001</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/362B599D-0191-42FB-9B1D-F4C6108537E9"><gtr:id>362B599D-0191-42FB-9B1D-F4C6108537E9</gtr:id><gtr:name>Chiesi Farmaceutici S.p.A.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Human Genetics</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/41907DE0-D69A-49CB-BBCF-A87DE7A3358A"><gtr:id>41907DE0-D69A-49CB-BBCF-A87DE7A3358A</gtr:id><gtr:name>Avan Biotech</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E30B7145-0051-47F4-B2D6-C93EE14B8568"><gtr:id>E30B7145-0051-47F4-B2D6-C93EE14B8568</gtr:id><gtr:name>University of Oslo</gtr:name><gtr:address><gtr:line1>Boks 1072 Blindern</gtr:line1><gtr:line4>Oslo</gtr:line4><gtr:line5>NO 0316</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8457F177-72B8-495C-B502-18A1EC2E4EFD"><gtr:id>8457F177-72B8-495C-B502-18A1EC2E4EFD</gtr:id><gtr:name>Flinders University</gtr:name><gtr:address><gtr:line1>Flinders University</gtr:line1><gtr:line2>Sturt Road, Bedford Park</gtr:line2><gtr:line3>GPO Box 2100</gtr:line3><gtr:line4>Adelaide</gtr:line4><gtr:postCode>5001</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A400BE25-0A67-4DC4-90E2-F3C57C400F4D"><gtr:id>A400BE25-0A67-4DC4-90E2-F3C57C400F4D</gtr:id><gtr:name>Technion Israel Institue of Technology</gtr:name><gtr:address><gtr:line1>Taub Building</gtr:line1><gtr:line2>Technion  Institute of Technology</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Israel</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/362B599D-0191-42FB-9B1D-F4C6108537E9"><gtr:id>362B599D-0191-42FB-9B1D-F4C6108537E9</gtr:id><gtr:name>Chiesi Farmaceutici S.p.A.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1AC5BEB3-3A70-4155-9983-17D62A961CE6"><gtr:id>1AC5BEB3-3A70-4155-9983-17D62A961CE6</gtr:id><gtr:firstName>Monica</gtr:firstName><gtr:surname>Berry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6A57D3BB-3572-4610-8DD1-E9705AA96B5F"><gtr:id>6A57D3BB-3572-4610-8DD1-E9705AA96B5F</gtr:id><gtr:firstName>Sajjad</gtr:firstName><gtr:surname>Ahmad</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8A99DCBD-0C0A-4AFB-89EE-04D2E15981FA"><gtr:id>8A99DCBD-0C0A-4AFB-89EE-04D2E15981FA</gtr:id><gtr:firstName>Anne</gtr:firstName><gtr:otherNames>Mary</gtr:otherNames><gtr:surname>Dickinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/630947FF-05A9-401E-A366-A17B09D02BE9"><gtr:id>630947FF-05A9-401E-A366-A17B09D02BE9</gtr:id><gtr:firstName>Francisco</gtr:firstName><gtr:otherNames>Carlos</gtr:otherNames><gtr:surname>Figueiredo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0900879"><gtr:id>B33A39E3-7ABC-4091-804E-2783151C027D</gtr:id><gtr:title>To evaluate the effectiveness of cultured human limbal epithelium for the treatment of limbal stem cell deficiency</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900879</gtr:grantReference><gtr:abstractText>The cornea is the clear window at the front of the eye and its clarity is vital for light transmission to the back of the eye for visual perception. Transparency of the cornea depends upon the integrity of its outermost layer called the epithelium, which is constantly regenerated throughout life by a population of stem cells found at the edge of the cornea in an area called the limbus, the so called limbal stem cells (LSC). If LSC becomes deficient as a result of injury or disease, this epithelium will breakdown leading to severe pain and blindness. This condition is often difficult to treat, however, the management of limbal stem cell deficiency (LSCD) has benefited from major breakthroughs in recent years. LSC from the patient?s own (one eye disease) or a relative healthy eye or from a cadaveric eye can grow in the laboratory and then transplanted to the diseased eye. This technique however uses animal products to help grow the cells with a great risk of diseases transmission. In addition, the safety and effectiveness of this treatment is rather difficult to establish due to the diversity and the small number of cases reported. Transplantation of cultured limbal epithelium can therefore not be recognized, enabling NHS funding, until its effectiveness and safety is determined by a formally structured clinical trial. Such a trial forms the main objective of this proposal. We have therefore developed an ?animal product free? technique for growing the cells in the laboratory in an ultra-clean environment and successfully transplanted 8 patients with LSCD in one eye by taking LSC from their healthy other eye. Despite of our success, this number of patients is not significant to draw proper conclusions. This proposal aims therefore to evaluate the safety and efficacy of our methods by treating more patients with total unilateral LSCD. Another aim of the project is to develop a freezing method of cultured human LSC for storage and to set-up a service to supply clinical grade cultured LSC for transplantation at other UK centres. In addition, this study will investigate the abnormal tear film in patients with LSCD to allow for a customised eye treatment. Finally, LSCD has an enormous impact on patient?s quality of life with serious detrimental effects on productivity and leisure activities. To that effect we have selected 4 questionnaires to look at different aspects of patients with LSCD and its treatment.</gtr:abstractText><gtr:technicalSummary>Limbal stem cell deficiency (LSCD) is a disease caused by the loss or dysfunction of limbal stem cells (LSC). In LSCD, the corneal epithelium integrity and function cannot be maintained and consequently epithelial defects occur causing persistent pain and severe visual impairment with marked patient morbidity, often affecting young adults and requiring frequent clinic visits. By far the most common cause is from chemical burns. The management of severe LSCD has benefited from major breakthroughs in recent years. In 1989, it was proposed that tissue limbal grafts could be used to treat LSCD. This involved tissue from the patient?s other healthy eye (autografts in unilateral cases) or from a living relative or cadaver (allografts in bilateral cases). In cases of autografts and living relatives, the donor eye is at risk of developing iatrogenic LSCD due to the large amounts of tissue required. In cases of allografts, systemic immunosuppression is required which is associated with enormous risk of toxicity. In 1997, Pellegrini and co-workers described a procedure using a small piece of autologous limbal tissue cultivated in vitro to treat two patients with unilateral alkali burns. This significantly reduces the risk of causing LSCD in the donor eye and eliminates the requirement of immunosuppression. Subsequently, other studies have been conducted, however the effectiveness of this treatment is impossible to establish due to the small number of cases reported and the heterogeneity of the studies. Transplantation of cultured limbal epithelium can therefore not be recognized as a treatment option for LSCD, enabling NHS funding, until its safety and effectiveness is established by a formally structured clinical trial. Such a trial forms the main objective of this proposal. We have successfully treated 8 consecutive patients with total unilateral LSCD using ex vivo expanded (animal free system and full GMP conditions) LSC autografts. Aims of this study is to evaluate: 
? The safety and effectiveness of cultured human LSC for the treatment of patients with unilateral total LSCD;
? Patients reported outcomes before and after LSC transplantation; 
? The tear film of patients with unilateral LSCD before and after LSC transplantation; 
? The predictive value of pre-operative OCT in terms of visual outcomes and the need for further surgery, e.g., penetrating keratoplasty; 
? To develop a cryopreservation method of culturing human LSC for storage and to set-up a national service to supply clinical grade ex vivo expanded LSC for transplantation at other UK centres.</gtr:technicalSummary><gtr:fund><gtr:end>2015-12-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1172575</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chiesi Farmaceutici S.p.A.</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Collaboration with Chiesi Farmaceutici SpA, Parma, Italy to develop cell therapy to treat limbal stem cell deficiency</gtr:description><gtr:id>8E4C232F-7D89-4156-8026-F16D9AF8B49C</gtr:id><gtr:impact>Setup a clinical trial and registry to treat patients with limbal stem cell deficiency using autologous cell therapy.</gtr:impact><gtr:partnerContribution>Provide the IMP, clinical protocol and financial support.</gtr:partnerContribution><gtr:piContribution>Setup a clinical trial and a registry with Chiesi using cell therapy to treat patients with unilateral and bilateral limbal stem cell deficiency</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Avan Biotech</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>The use of new animal origin-free cell culture suplements known as HKSdaFREE, HKGE2, HEGE and CRYOVIVE for LSC culture</gtr:description><gtr:id>E0E7FA69-1E6C-40AF-9F71-BB964949FEED</gtr:id><gtr:impact>The collaboration is at an early stage and there is no output yet.</gtr:impact><gtr:partnerContribution>The aim is to potentially use a better clinical grade/animal free culture medium that will be commercially availble to grow limbal stem cells for transplantation.</gtr:partnerContribution><gtr:piContribution>We are currently growing ex vivo limbal stem cells (LSC) using the above animal-free culture medium to compare with our normal epithelial medium.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences Bristol</gtr:department><gtr:description>Assessment of pre-corneal tear film in patients with unilateral total limbal stem cell deficeincy before and after autologous limbal stem cell transplantation.</gtr:description><gtr:id>93320DCA-8C62-45AA-869A-3E02DF44768E</gtr:id><gtr:impact>No output yet as this component of the project is due to start in the new year.</gtr:impact><gtr:partnerContribution>The Collaborator will assist to characterize changes in pre-corneal fluid before and after stem cell transplantation for the treatment of unilateral total limbal stem cell deficeincy.</gtr:partnerContribution><gtr:piContribution>Assited in original grant application.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technion - Israel Institute of Technology</gtr:collaboratingOrganisation><gtr:country>Israel, State of</gtr:country><gtr:department>Ruth and Bruce Rappaport Faculty of Medicine</gtr:department><gtr:description>Collaboration with Dr Ruby Shalom-Feuerstein, Rappaport Faculty of Medicine of the Technion, Haifa, israel on a grabt application to BIRAX Third Call for Proposal (Deadline 12 May 2016)</gtr:description><gtr:id>52A2CF8D-737E-4AC1-98F3-8ACB3EF53C0A</gtr:id><gtr:impact>Writing grant application to BIRAX 3rd call (deadline 12 May 2016).</gtr:impact><gtr:partnerContribution>Jointly writng a grant proposal to BIRAX 3rd Call (Deadline: 12 May 2016).</gtr:partnerContribution><gtr:piContribution>Professor Majlinda Lako has been working together with Professor Figueiredo and Dr Ruby Shalom-Feuerstein on a grant application to BIRAX 3rd Call for a collaborative research proposal looking at limbal stem cell heterogeneity.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences Bristol</gtr:department><gtr:description>Cryopreservation of cultured human limbal epithelium</gtr:description><gtr:id>6D371E74-AAD5-4F35-8EDF-E7D3B7E76E25</gtr:id><gtr:impact>We have just started this project 6 months ago therefore not in a position to report any substantive outcome yet.</gtr:impact><gtr:partnerContribution>The Collaborator is an internatinally known expert in cryobiology, he has been instrumental in setting up the projectThe Collaborator will assist on analysis and interpretation of Quality of Life instruments including the NEI-VFQ25 quality of vision subscale and pain/visual impairment scores. The Collaborator will assist to characterize changes in pre-corneal fluid before and after stem cell transplantation in patients with unilateral total limbal stem cell deficiency.</gtr:partnerContribution><gtr:piContribution>Optimization of a protocol for cryopreservation of human limbal epithelial cell cultures based on cell survival. The development of appropriate assays to determine the survival of cells after freezing and thawing are crucial to the successful outcome of the project. In addition to investigate potentially harmful effects of cryoprotectants on Limbal Stem Cells in the absence of freezing and to determine the optimum cooling and warming rates.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Flinders University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Ophthalmology Flinders</gtr:department><gtr:description>Cryopreservation of cultured human limbal epithelium</gtr:description><gtr:id>9AA19C78-272C-48D6-9023-ACFBF5FAA2F2</gtr:id><gtr:impact>We have just started this project 6 months ago therefore not in a position to report any substantive outcome yet.</gtr:impact><gtr:partnerContribution>The Collaborator is an internatinally known expert in cryobiology, he has been instrumental in setting up the projectThe Collaborator will assist on analysis and interpretation of Quality of Life instruments including the NEI-VFQ25 quality of vision subscale and pain/visual impairment scores. The Collaborator will assist to characterize changes in pre-corneal fluid before and after stem cell transplantation in patients with unilateral total limbal stem cell deficiency.</gtr:partnerContribution><gtr:piContribution>Optimization of a protocol for cryopreservation of human limbal epithelial cell cultures based on cell survival. The development of appropriate assays to determine the survival of cells after freezing and thawing are crucial to the successful outcome of the project. In addition to investigate potentially harmful effects of cryoprotectants on Limbal Stem Cells in the absence of freezing and to determine the optimum cooling and warming rates.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences Bristol</gtr:department><gtr:description>Cryopreservation of cultured human limbal epithelium</gtr:description><gtr:id>AD5E0BE0-C464-431A-A539-487B782E1AD9</gtr:id><gtr:impact>We have just started this project 6 months ago therefore not in a position to report any substantive outcome yet.</gtr:impact><gtr:partnerContribution>The Collaborator is an internatinally known expert in cryobiology, he has been instrumental in setting up the projectThe Collaborator will assist on analysis and interpretation of Quality of Life instruments including the NEI-VFQ25 quality of vision subscale and pain/visual impairment scores. The Collaborator will assist to characterize changes in pre-corneal fluid before and after stem cell transplantation in patients with unilateral total limbal stem cell deficiency.</gtr:partnerContribution><gtr:piContribution>Optimization of a protocol for cryopreservation of human limbal epithelial cell cultures based on cell survival. The development of appropriate assays to determine the survival of cells after freezing and thawing are crucial to the successful outcome of the project. In addition to investigate potentially harmful effects of cryoprotectants on Limbal Stem Cells in the absence of freezing and to determine the optimum cooling and warming rates.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oslo</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>collaboration with Dr. Tor Utheim's group, Norway</gtr:description><gtr:id>D9F2EF55-0EFF-407B-BB47-96036B179126</gtr:id><gtr:impact>not yet</gtr:impact><gtr:partnerContribution>Dr.Utheim's team is sharing data with our group with regard to transport conditions for limbal biopsies as well as ex vivo cultured LSCs.</gtr:partnerContribution><gtr:piContribution>We are sharing with Dr. Utheim's group our culture system for the ex vivo expansion of LSCs on human amniotic membrane.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of York</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Dr Julie Glanville on a NIHR grant application to the Research for Patient Benefit Programme on: &amp;quot;A systematic literature review and meta-analysis of cellular therapies for the treatment of limbal stem cell deficiency affecting one or both eyes&amp;quot;</gtr:description><gtr:id>A2CCEFE0-D276-4B97-BE1A-2BE07A4F7D75</gtr:id><gtr:impact>NIHR Grant Application submission deadline: 15 March 2016.</gtr:impact><gtr:partnerContribution>As above</gtr:partnerContribution><gtr:piContribution>Writing a joint grant application to the NIHR RfPB Programme on: &amp;quot;A systematic literature review and meta-analysis of cellular therapies for the treatment of limbal stem cell deficiency affecting one or both eyes&amp;quot;.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Flinders University</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>Ophthalmology Flinders</gtr:department><gtr:description>Quality of Life analysis of limbal stem cell transplantation for the treatment of total unilateral limbal stem cell deficiency.</gtr:description><gtr:id>5754810C-FED8-4C42-AC33-EB0B9B7CEF05</gtr:id><gtr:impact>No output yet as this part of the project is due to start in the new year.</gtr:impact><gtr:partnerContribution>The Collaborator will assist on data analysis and interpretation of Quality of Life Questionnaires, inlcuding NEI-VFQ25 quality of vision subscale and pain/visual impairment scores</gtr:partnerContribution><gtr:piContribution>The collaborator wil asssit on data anlysis and interpretation of quality of life questionnaires, inclusing NEI-VFQ25 quality of vision subscale and pain/visual impairment scores</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>113th Deutsche Ophthalmologishche Gesellschaft (DOG) Annual Congress. 1st  October 2015. Estrel Conference Centre, Berlin, Germany.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6330F514-BF0C-4D2A-AD40-1BC8026B6599</gtr:id><gtr:impact>Invited Internationals speaker on: &amp;quot;Ex vivo expanded autologous OME transplantation for treatment of bilateral total limbal stem cell deficiency&amp;quot;. The talk generated an enormous interest and debate on availability of cell therapy to treat unilateral and bilateral limbal stem cell deficiency. We are setting up a potential collaboration on limbal stem cell research with Professor Daniel Meller from Jena, Germany</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>national limbal stem cell workshop</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>56332D80-6FA1-464D-B1B6-BD1F442DE527</gtr:id><gtr:impact>Dr. Bojic from Lako and Figueiredo group attended the workshop and presented our work.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>6th EU Cornea. 4-5 September 2015. Barcelona, Sapin.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C1949860-8A86-4492-A102-A06AD693C898</gtr:id><gtr:impact>Giving a talk to a mixture of clinical and research scientists audience with main interest in cell therapy to treat limbal stem cell deficiency. The talk generated excellent discussion on the subject of &amp;quot;Stem cell transplantation in bilateral limbal deficiency&amp;quot;, with special interest in our primary research on ex vivo expanded autologous oral mucosa epithelium to treat patients with bilateral stem cell deficiency.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Human Cloning and Stem Cell research Through the Medium of Law</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9A6E419C-5C37-4F53-B1D3-725A80F6BB82</gtr:id><gtr:impact>My presentation generated a lot of thinking and discussions regarding visual impairment, stem cell research, stem cell application in humans, rare diseases

After my talk students asked if they could visit the stem cell laboratory</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regenerative medicine - stem cells, genetic engineering and biotechnology&quot; Congress</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FDFA6F44-C6EF-402D-BAE6-284118FD956F</gtr:id><gtr:impact>200 people attended the talk
location Bosnia Herzegovina-Banja Luka, 21st september 2012

The talk raised high interest amongst the opthalmic clinicians and we have received a number of invitations to collaborate</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to the Department of Ophthalmology and Research Laboratory, University Hospitals of Geneva, Switzerland.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>C9D94873-94AA-4D8E-B9E1-705001BC2821</gtr:id><gtr:impact>This visit to the Department of Ophthalmology and the Research Laboratory of Department of Clinical Neurosciences, University Hospitals of Geneva, Switzerland. 4 - 6 March 2013. I had the opportunity to give a talk on the Limbal Stem Cell research Project to Ophthalmologists and scientists (50 people).

Established strong links with the department and currently exploring potential research collaboration.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker at the MipTec 2014 - The Leading European Event for Drug Discovery</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0381796E-F949-4907-8E85-CC8D5F17CB43</gtr:id><gtr:impact>Following Prof. Lako's talk in this conference, a new collaboration is being set up with Roche Pharmauceticals.

An exchange scheme for postdoctoral scientists between Lako's lab and Roche is being set up following the talk in this conference.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nordic Ophthalmological Conference, Aarhus, Denmark</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>21C4A776-AD2A-4EDE-99FF-8DE9591A2892</gtr:id><gtr:impact>Special session of the Nordic Ophthalmological Conference on stem cells/regenerative medicine</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Regenerative Medicine Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BB853588-2F74-4BA4-AC9F-534EFE3CF2D0</gtr:id><gtr:impact>around 300 people attended the talk
location: Skopje/Macedonia, March 2011

the talk raised interest amongst opthalmic clinicians and a few biotech companies with respect to cryopreservation of corneal epithelial stem cells</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Limbal stem cell therapy - EU market authorisation license</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2D606F2-676C-4CB4-A751-A6F1BC6FD585</gtr:id><gtr:impact>Workshop discussion at the Society of Legal Scholars Annual Seminar 2015 - Incentivising Innovation and Higher Standards in Regulations and Liability Relating to Medicines - 25th March 2015. Durham University, Durham, UK. This led to a collaboration with Professor Shaun Pattinson, Chair of Medical Law and Ethics &amp;amp; Deputy Head of Durham Law School.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>XXIX Annual Meeting of the European Eye Bank Association. 19-21 January 2017. Prague, Czech Republic.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4BC38A3C-A015-4648-B696-FC343419FFC9</gtr:id><gtr:impact>SIG on Regenerative Medicine</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>7th EU Cornea Symposium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AAAEE5E6-C920-46B8-AA99-2F5A260BC1A3</gtr:id><gtr:impact>EU Cornea special symposium on limbal stem cells</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited panellist of the European Opthalmology Futures Forum, London 11th September</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AA522D5E-DA28-4714-941F-0709BD98021A</gtr:id><gtr:impact>Prof. Lako was part of the panel describing the impact of gene and stem cell therapy for treatment of blindness.

press release plus publication</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>XXVIII Annual Meeting of the European Eye Bank Association. 22-23 January 2016. Aarhus, Denmark.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F2BC1DDA-BBEF-47D3-B6ED-1286ED048EC2</gtr:id><gtr:impact>Invited speaker to give a talk on: Molecular analysis of inflammation in corneal pannus tissue from patients with total limbal stem cell deficiency by quantitative real time PCR&amp;quot;. Since then I have been invited to be a member of the European Eye Bank Association Special Interest Group on Limbal Stem Cells.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Association for Research in Vision and Ophthalmology (ARVO) Annual meeting, Denver, Colorado, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>920B7F44-A92F-4261-B0E4-759391B05201</gtr:id><gtr:impact>I presented a talk on &amp;quot;Patient reported outcomes before and following ex vivo cultured autologous limbal stem cell transplantation for total unilateral limbal stem cell deficiency&amp;quot;. This generated a lot of discussions and further collaboration with Professor Konrad Pesudovs from Flinders University, Australia.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Genetics Matter Day</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7A465BEF-7945-4432-87FA-4314AA079BAB</gtr:id><gtr:impact>Around 100 members of the public attend the Genetics Matter Day organised by the Institute of Genetic Medicine each year. Prof. Lako's group organises an &amp;quot;eye table&amp;quot; stimulating discussion on eye diseases and stem cell treatments.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public debate: &quot;Future of Stem Cell Debate&quot;. Invited panellist</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>6A094B74-DC39-4383-9094-5D36147BC150</gtr:id><gtr:impact>200 people attended the debate. They were very active and asked a number of questions throughout the whole debate.

Increased public awareness of our research project. This initiative generated more interest in the project that was followed by a number of emails from the public.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visiting Professor to Federal University of Pernambuco, Recife, Brazil.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FD9CB57A-BC39-4FBE-84A3-40A68D776085</gtr:id><gtr:impact>This visit to Department of Ophthalmology and the Laboratory of Immunopathology Keizo Asami (LIKA), Recife, Pernambuco, Brazil, 18 - 20 March 2013. I had the opportunity to give 2 talks on the Limbal Stem Cell research Project: 1. to Ophthalmologists and scientists at the Federal University of Pernambuco (50 people) and 2. at the XIX Norte-Nordeste Ophthalmology Congress (800 people). 21 -23 March 2013. Recife, Brazil.

Contacts have been established with potential for future collaborations and interchange of scientists visiting our labs or even to engage in a higher degree.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation at EU Cornea Limbal Stem Cell Symposium in Amsterdam</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>458175C6-1444-495B-99FD-A534DF7F3256</gtr:id><gtr:impact>60 ophthalmologists form around the world attended this symposium on limbal tem cells. I gave a talk on: Limbal Stem Cell Culture: Explant vs. Dissociated Cells.

Opportunity to discuss potential collaborations with stem cell colleagues from Europe. In particular on cell shipment.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:url>http://www.eucornea.org</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Single Cell Genomics Unit</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/M008886/1</gtr:fundingRef><gtr:id>A3319594-62FC-4F92-A1C8-E759446E9B95</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>144908</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR Research for Patient Benefit</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:fundingRef>PB-PG-1215-20037</gtr:fundingRef><gtr:id>57D3B8F0-9305-41CA-995F-D6E1AAC9DA6B</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42111</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Capability Funding</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>RCF141508</gtr:fundingRef><gtr:id>847D46F1-A209-4B9D-A7A8-892551D23BC3</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46482</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Confidence in Concept</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MC_PC_15030</gtr:fundingRef><gtr:id>849920D9-DC51-4831-BAE5-9CE957FDA252</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42100</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Newcastle Biomedical Research Centre</gtr:department><gtr:description>NIHR Newcastle BRC Support Research Development and Infrastrucutre</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>RCF141508</gtr:fundingRef><gtr:id>4D48D3DA-8F04-48D4-9D7E-A562630861B9</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Health Improvement</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Academic Health Science Network for the North East and North Cumbria</gtr:fundingOrg><gtr:fundingRef>219</gtr:fundingRef><gtr:id>3399701D-DA69-4340-93C5-A14C1CCB7EAB</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>28600</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fund to Support Generation of Data for Patent FMS Newcastle University</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>University of Newcastle</gtr:fundingOrg><gtr:id>0A74F783-5641-4BC9-9485-F9DB110F6386</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Corneal epithelial stem cell therapy: enhancing safety and stability of cultured product</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Yorkshire and Humber Academic Health Science Network</gtr:fundingOrg><gtr:id>203FC504-DEE4-48BA-B1F1-52CF1E7B2279</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Newcastle Biomedical Research Centre</gtr:department><gtr:description>National Institute of Health Research Newcastle Biomedial Research Centre</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:id>2C03568B-E76A-4282-A33E-0D640F81D3B9</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>This patent describes our method of ex vivo expansion of limbal stem cells on human amniotic membrane.</gtr:description><gtr:id>3952AB4E-06A6-42DF-A79F-82E388B78193</gtr:id><gtr:impact>no impacts yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>NL/P213205GB</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Limbal Stem cell graft manufacture methods (Narrow); University of Newcastle upon Tyne; #SL104#</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This patent describes the culture method for the ex vivo expansion of oral mucosa epithelial cells on human amniotic membrane.</gtr:description><gtr:id>B7F062A7-BF39-483E-BD61-D0B9638F8AE5</gtr:id><gtr:impact>no impacts yet</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>KLT/P210577GB</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Oral Mucosa in Limbal Stem Cell Deficiency; University of Newcastle upon Tyne; #SL104#</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Invited Member of the European Eye Bank Assocaition Special Interest Group for &amp;quot;Advanced Therapy Medicinal Products&amp;quot; since Feb 2016. Main aim of this SIG: to write standards/recommendations that the EEBA Committee could then circulate among the members, and also to furnish informed comment to external agencies whenever such possibilities arise. In addition, to write editorials/reviews.</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>801BFABC-BD22-400A-8111-1AFA9C07CC3D</gtr:id><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>International Limbal Stem Cell Workshop</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>E4BAC480-8147-4660-851B-BEBC43CA39C6</gtr:id><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Phase II clinical Trial to evaluate the long-term safety and efficacy of Transplantation of an animal-free, GMP compliant, cultivated autologous limbal epithelial stem cells on human amniotic membrane (HAM) for treatment of patients with unilateral total limbal stem cell deficiency (LSCD).</gtr:description><gtr:id>D6146D0D-85B4-471A-9152-17E000E74646</gtr:id><gtr:impact>Phase I study has demonstrated an improvement in patient QoL with consequent Improvement in patient care using an animal free cell culture technique. Currently engaged in a Phase II study to demonstrate its safety and efficacy.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Ex vivo Expansion of Autologous Limbal Stem Cell for Transplantation in Patients with Unilateral Limbal Stem Cell Deficiency</gtr:title><gtr:type>Therapeutic Intervention - Surgery</gtr:type><gtr:ukcrnIsctnId>ISRCTN51772481</gtr:ukcrnIsctnId><gtr:url>http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=11185</gtr:url><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Designed a database to collect all relevant clinical information from our phase II clinical trial on ex vivo expansion autologous limbal stem cells for treatment of patients with unilateral limbal stem cell deficiency</gtr:description><gtr:id>ADB893BA-D6B8-4B52-804A-AE6FFCC1839C</gtr:id><gtr:impact>enormous contribution to data collection that will facilitate data analysis and provide added safety to our clinical trial</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Limbal Stem Cell MACRO Database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/31D5186A-1357-4337-A68B-AC89A0FD4A8B"><gtr:id>31D5186A-1357-4337-A68B-AC89A0FD4A8B</gtr:id><gtr:title>The limbal epithelium of the eye--a review of limbal stem cell biology, disease and treatment.</gtr:title><gtr:parentPublicationTitle>BioEssays : news and reviews in molecular, cellular and developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/556fd8969cc458a99fa1955112bbfcd8"><gtr:id>556fd8969cc458a99fa1955112bbfcd8</gtr:id><gtr:otherNames>Osei-Bempong C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0265-9247</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C89709A1-E602-491D-8201-3892039C5CFC"><gtr:id>C89709A1-E602-491D-8201-3892039C5CFC</gtr:id><gtr:title>The culture and transplantation of human limbal stem cells.</gtr:title><gtr:parentPublicationTitle>Journal of cellular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9541</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD20039E-D5B0-42CE-AE11-7C68AAF14624"><gtr:id>AD20039E-D5B0-42CE-AE11-7C68AAF14624</gtr:id><gtr:title>Successful application of ex vivo expanded human autologous oral mucosal epithelium for the treatment of total bilateral limbal stem cell deficiency.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91ade9479bb633e247d863554bb61df3"><gtr:id>91ade9479bb633e247d863554bb61df3</gtr:id><gtr:otherNames>Kolli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C910B93-C345-4F25-996C-5904D26DDF6B"><gtr:id>8C910B93-C345-4F25-996C-5904D26DDF6B</gtr:id><gtr:title>13 years of cultured limbal epithelial cell therapy: a review of the outcomes.</gtr:title><gtr:parentPublicationTitle>Journal of cellular biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/06ec9f3e4ff8da4fa711f9c1bb44eaf9"><gtr:id>06ec9f3e4ff8da4fa711f9c1bb44eaf9</gtr:id><gtr:otherNames>Baylis O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0730-2312</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/33067BAB-6CD2-426D-8BB4-5494CE4FDFA1"><gtr:id>33067BAB-6CD2-426D-8BB4-5494CE4FDFA1</gtr:id><gtr:title>An important role for adenine, cholera toxin, hydrocortisone and triiodothyronine in the proliferation, self-renewal and differentiation of limbal stem cells in&amp;nbsp;vitro.</gtr:title><gtr:parentPublicationTitle>Experimental eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6a0029150620f65feff65f8b10d27745"><gtr:id>6a0029150620f65feff65f8b10d27745</gtr:id><gtr:otherNames>Yu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0014-4835</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9AF389D-AF79-47A5-9C85-86A4E1BD8D28"><gtr:id>F9AF389D-AF79-47A5-9C85-86A4E1BD8D28</gtr:id><gtr:title>Successful clinical implementation of corneal epithelial stem cell therapy for treatment of unilateral limbal stem cell deficiency.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/91ade9479bb633e247d863554bb61df3"><gtr:id>91ade9479bb633e247d863554bb61df3</gtr:id><gtr:otherNames>Kolli S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C3F95617-A3CB-47B5-81B9-BD8C09CEC5EA"><gtr:id>C3F95617-A3CB-47B5-81B9-BD8C09CEC5EA</gtr:id><gtr:title>An investigation of donor and culture parameters which influence epithelial outgrowths from cultured human cadaveric limbal explants.</gtr:title><gtr:parentPublicationTitle>Journal of cellular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/06ec9f3e4ff8da4fa711f9c1bb44eaf9"><gtr:id>06ec9f3e4ff8da4fa711f9c1bb44eaf9</gtr:id><gtr:otherNames>Baylis O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9541</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FF8B8A00-7663-4DBD-BA49-BAE9B2E9A3DB"><gtr:id>FF8B8A00-7663-4DBD-BA49-BAE9B2E9A3DB</gtr:id><gtr:title>Stem cell therapies for ocular surface disease.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/378c2178deeae7c8e4ad76a33c2416f8"><gtr:id>378c2178deeae7c8e4ad76a33c2416f8</gtr:id><gtr:otherNames>Ahmad S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900879</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>